Aloperine and Its Derivatives as a New Class of HIV-1 Entry Inhibitors

ACS Medicinal Chemistry Letters

Volumn 7, Issue 3, 2016, Pages 240-244

  Dang, Zhao ^a   Zhu, Lei ^a   Lai, Weihong ^a   Bogerd, Hal ^a   Lee, Kuo Hsiung ^b,c   Huang, Li ^a   Chen, Chin Ho ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

aloperine; entry inhibitor; HIV 1

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ALOPERINE; ALOPERINE DERIVATIVE; FOSTEMSAVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; N (1 BUTYL) 4 TRIFLUOROMETHOXY BENZAMIDE; TEMSAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS ENTRY;

EID: 84960893518     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00339     Document Type: Article

References (33)

1. CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data-United States and 6 dependent areas-2012. HIV surveillance supplemental report 2014; 19 (No.3), 2014.
2. UNAIDS (Geneva). Fact sheet: 2014 Global statistics. (2015.
3. Dau, B.; Holodniy, M. Novel targets for antiretroviral therapy: clinical progress to date Drugs 2009) 69, 31-50 10.2165/00003495-200969010-00003
4. Pereira, C. F.; Paridaen, J. T. Anti-HIV drug development-an overview Curr. Pharm. Des. 2004, 10, 4005-4037 10.2174/1381612043382459
5. Chun, T. W.; Carruth, L.; Finzi, D.; Shen, X.; DiGiuseppe, J. A.; Taylor, H.; Hermankova, M.; Chadwick, K.; Margolick, J.; Quinn, T. C.; Kuo, Y. H.; Brookmeyer, R.; Zeiger, M. A.; Barditch-Crovo, P.; Siliciano, R. F. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection Nature 1997, 387, 183-188 10.1038/387183a0
6. Wong, J. K.; Hezareh, M.; Günthard, H. F.; Havlir, D. V.; Ignacio, C. C.; Spina, C. A.; Richman, D. D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia Science 1997, 278, 1291-1295 10.1126/science.278.5341.1291
7. Finzi, D.; Hermankova, M.; Pierson, T.; Carruth, L. M.; Buck, C.; Chaisson, R. E.; Quinn, T. C.; Chadwick, K.; Margolick, J.; Brookmeyer, R.; Gallant, J.; Markowitz, M.; Ho, D. D.; Richman, D. D.; Siliciano, R. F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy Science 1997, 278, 1295-1300 10.1126/science.278.5341.1295
8. Persaud, D.; Zhou, Y.; Siliciano, J. M.; Siliciano, R. F. Latency in human immunodeficiency virus type 1 infection: no easy answers J. Virol. 2003, 77, 1659-1665 10.1128/JVI.77.3.1659-1665.2003
9. Kilby, J. M.; Hopkins, S.; Venetta, T. M.; DiMassimo, B.; Cloud, G. A.; Lee, J. Y.; Alldredge, L.; Hunter, E.; Lambert, D.; Bolognesi, D.; Matthews, T.; Johnson, M. R.; Nowak, M. A.; Shaw, G. M.; Saag, M. S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry Nat. Med. 1998, 4, 1302-1307 10.1038/3293
10. Van Der Ryst, E. Maraviroc-A CCR5 antagonist for the treatment of HIV-1 infection Front. Immunol. 2015, 6, 277 10.3389/fimmu.2015.00277
11. Patel, R. V.; Park, S. W. Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase Bioorg. Med. Chem. 2015, 23, 5247-5263 10.1016/j.bmc.2015.06.016
12. Yuan, X.; Huang, L.; Ho, P.; Labranche, C.; Chen, C.-H. Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564 Virology 2004, 324, 525-530 10.1016/j.virol.2004.04.009
13. Huang, L.; Lai, W.-H.; Ho, P.; Chen, C.-H. Induction of a nonproductive conformational change in gp120 by a small molecule HIV-1 entry inhibitor AIDS Res. Hum. Retroviruses 2007, 23, 28-32 10.1089/aid.2006.0137
14. Lai, W.-H.; Huang, L.; Ho, P.; Li, Z.-J.; Montefiori, D.; Chen, C.-H. Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of HIV-1 Antimicrob. Agents Chemother. 2008, 52, 128-136 10.1128/AAC.00737-07
15. Bocharnikova, A. V.; Massagetov, P. S. The alkaloids of Leptorhabdos parviflora Benth Zh. Obshch. Khim. 1964, 34, 1025-1028
16. Brosius, A. D.; Ziller, J. W.; Zhang, Q. M Relative and absolute configuration of aloperine Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1997, C5310, 1510-1512 10.1107/S0108270197009244
17. Dang, Z.; Jung, K.; Zhu, L.; Lai, W.-H.; Xie, H.; Lee, K. H.; Huang, L.; Chen, C.-H. Identification and synthesis of quinolizidines with anti-influenza A virus activity ACS Med. Chem. Lett. 2014, 5, 942-946 10.1021/ml500236n
18. deCamp, A.; Hraber, P.; Bailer, R. T.; Seaman, M. S.; Ochsenbauer, C.; Kappes, J.; Gottardo, R.; Edlefsen, P.; Self, S.; Tang, H.; Greene, K.; Gao, H.; Daniell, X.; Sarzotti-Kelsoe, M.; Gorny, M. K.; Zolla-Pazner, S.; LaBranche, C. C.; Mascola, J. R.; Korber, B. T.; Montefiori, D. C. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies J. Virol. 2014, 88, 2489-24507 10.1128/JVI.02853-13
19. Huang, L.; Xiong, Y.; Aiken, C.; Chen, C.-H. Bifunctional anti-HIV-1 small molecules with two novel mechanisms of action Antimicrob. Agents Chemother. 2004, 48, 663-665 10.1128/AAC.48.2.663-665.2004
20. Huang, L.; Ho, P.; Lee, K. H.; Chen, C.-H. Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives Bioorg. Med. Chem. 2006, 14, 2279-2289 10.1016/j.bmc.2005.11.016
21. Dang, Z.; Lai, W.; Ho, P.; Zhu, L.; Qian, K.; Lee, K. H.; Huang, L.; Chen, C.-H. New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1 J. Med. Chem. 2013, 56, 2029-2037 10.1021/jm3016969
22. Dang, Z.; Qian, K.; Ho, P.; Zhu, L.; Lee, K. H.; Huang, L.; Chen, C. H. Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants Bioorg. Med. Chem. Lett. 2012, 22, 5190-5194 10.1016/j.bmcl.2012.06.080
23. Yang, Z.; Zadjura, L.; D'Arienzo, C.; Marino, A.; Santone, K.; Klunk, L.; Greene, D.; Lin, P. F.; Colonno, R.; Wang, T.; Meanwell, N.; Hansel, S. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics Biopharm. Drug Dispos. 2005, 26, 387-402 10.1002/bdd.471
24. Liu, T.; Huang, B.; Zhan, P.; De Clercq, E.; Liu, X. Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction derived from BMS-378806 Eur. J. Med. Chem. 2014, 86, 481-490 10.1016/j.ejmech.2014.09.012
25. Kadow, J. F.; Ueda, Y.; Meanwell, N. A.; Connolly, T. P.; Wang, T.; Chen, C. P.; Yeung, K. S.; Zhu, J.; Bender, J. A.; Yang, Z.; Parker, D.; Lin, P. F.; Colonno, R. J.; Mathew, M.; Morgan, D.; Zheng, M.; Chien, C.; Grasela, D. Inhibitors of human immunodeficiency virus type 1 (HIV-1), attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043) J. Med. Chem. 2012, 55, 2048-2056 10.1021/jm201218m
26. Langley, D. R.; Kimura, S. R.; Sivaprakasam, P.; Zhou, N.; Dicker, I.; McAuliffe, B.; Wang, T.; Kadow, J. F.; Meanwell, N. A.; Krystal, M. Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action Proteins: Struct., Funct., Genet. 2015, 83, 331-350 10.1002/prot.24726
27. Lin, P. F.; Blair, W.; Wang, T.; Spicer, T.; Guo, Q.; Zhou, N.; Gong, Y. F.; Wang, H. G.; Rose, R.; Yamanaka, G.; Robinson, B.; Li, C. B.; Fridell, R.; Deminie, C.; Demers, G.; Yang, Z.; Zadjura, L.; Meanwell, N.; Colonno, R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 11013-11018 10.1073/pnas.1832214100
28. Guo, Q.; Ho, H. T.; Dicker, I.; Fan, L.; Zhou, N.; Friborg, J.; Wang, T.; McAuliffe, B. V.; Wang, H. G.; Rose, R. E.; Fang, H.; Scarnati, H. T.; Langley, D. R.; Meanwell, N. A.; Abraham, R.; Colonno, R. J.; Lin, P. F. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions J. Virol. 2003, 77, 10528-10536 10.1128/JVI.77.19.10528-10536.2003
29. Si, Z.; Madani, N.; Cox, J. M.; Chruma, J. J.; Klein, J. C.; Schon, A.; Phan, N.; Wang, L.; Biorn, A. C.; Cocklin, S.; Chaiken, I.; Freire, E.; Smith, A. B.; III; Sodroski, J. G. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 5036-5041 10.1073/pnas.0307953101
30. Hoffman, T. L.; LaBranche, C. C.; Zhang, W.; Canziani, G.; Robinson, J.; Chaiken, I.; Hoxie, J. A.; Doms, R. W. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 6359-6364 10.1073/pnas.96.11.6359
31. Li, Z.; Zhou, N.; Sun, Y.; Ray, N.; Lataillade, M.; Hanna, G. J.; Krystal, M. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors Antimicrob. Agents Chemother. 2013, 57, 4172-4180 10.1128/AAC.00513-13
32. Henrich, T. J.; Kuritzkes, D. R. HIV-1 entry inhibitors: recent development and clinical use Curr. Opin. Virol. 2013, 3, 51-57 10.1016/j.coviro.2012.12.002
33. Lalezari, J. P.; Latiff, G. H.; Brinson, C.; Echevarría, J.; Treviño-Pérez, S.; Bogner, J. R.; Thompson, M.; Fourie, J.; Sussmann Pena, O. A.; Mendo Urbina, F. C.; Martins, M.; Diaconescu, I. G.; Stock, D. A.; Joshi, S. R.; Hanna, G. J.; Lataillade, M. AI438011 study team. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial Lancet HIV 2015, 2 (10) e427-37 10.1016/S2352-3018(15)00177-0